This study will test nabilone as a treatment for agitation in persons living with Alzheimer's disease. Nabilone is a Health Canada approved medication based on Tetrahydrocannabinol (THC), a chemical from the cannabis (marijuana) plant. Participants in this study will randomly be assigned to receive either nabilone medication or a non-active treatment (i.e. placebo) for 9 weeks. This study will look at how nabilone helps with agitation, behavioural symptoms and caregiver difficulties.
Eligibility Criteria
- Age Range: Ages 55 or older
- Diagnosis of Alzheimer's disease or vascular dementia
- Experiencing agitation
- You have a study partner to accompany to study visits and co-participate
What does the study involve?
- Number of contacts: 7-9 visits
- Format of study: Hybrid (mix of in-person and virtual visits)
- Compensation offered? Yes
Investigator(s): Dr. Sanjeev Kumar
Full Study Title: Nabilone for Agitation Blinded Intervention Trial (NAB-IT)
Contact Information:
E-mail: NAB-IT@camh.ca
REB number: 1968
REB Approval Expiry Date: March 6, 2026
PLEASE NOTE:
- Research staff cannot give medical advice over the phone or via email.
- If you have specific questions regarding your health care, please contact your family physician.
- We regret that not everyone screened for a study will be eligible to participate
- For more information about other treatment options for mental illness or addiction offered by CAMH, visit www.camh.ca or call 416-535-8501.